NHS to Offer Improved Stop Smoking Pill in England

Nov.15.2024
NHS to Offer Improved Stop Smoking Pill in England
NHS will start offering an "improved" stop smoking pill to tens of thousands of people in England who want to quit cigarettes.

According to a recent report by the BBC, the National Health Service (NHS) in the UK will begin offering an "improved" stop smoking pill to tens of thousands of people in England who are looking to quit smoking.

 

The NHS has stated that Varenicline is as effective as e-cigarettes and more effective than nicotine replacement gum or patches.

 

This medication can suppress nicotine addiction and was previously marketed under the brand name Champix on the NHS several years ago. However, it was withdrawn due to some impurity issues. The new version has now been approved as safe.

 

Officials stated that e-cigarettes are sometimes provided, typically by local NHS stop smoking services, with an initial e-cigarette starter kit provided for approximately two weeks.

 

Varenicline is a prescription medication, which means people cannot purchase it over the counter at a pharmacy or supermarket and instead need to see their general practitioner (GP) or NHS stop smoking service to obtain it. It works by reducing cravings for nicotine and blocking its effects on the brain, while also helping to alleviate withdrawal symptoms such as irritability or difficulty sleeping.

 

The NHS states that it has been proven to help approximately one quarter of people quit smoking for at least six months when used in conjunction with behavioral support, such as counseling. The study suggests that this could help over 85,000 people quit smoking each year and potentially prevent around 9,500 smoking-related deaths in the next five years.

 

Health and Social Care Secretary Wes Streeting said: "The rollout of this pill can save the NHS millions of pounds, save appointments to help other patients be seen faster and save lives."

 

NHS CEO Amanda Pritchard announced at the annual NHS Providers conference that this drug could be a "game-changer" for those looking to quit smoking.

 

Due to e-cigarettes not being licensed as medication, general practitioners are unable to prescribe e-cigarettes for individuals attempting to quit smoking unless approved by the local NHS. However, some local governments do indeed provide e-cigarettes for smokers wanting to quit.

 

The guidelines suggest that people first try to obtain licensed smoking cessation medications, even though e-cigarettes are recognized as a smoking cessation aid. The harms of e-cigarettes are far less than smoking.

 

However, health experts unanimously agree that people should not start using e-cigarettes unless it is for smoking cessation.

 

Hazel Cheeseman, chief executive of Action on Smoking and Health, said access to services was variable.

 

"Wherever a smoker lives, they should be able to access the most effective forms of treatment to help them stop," she said.

 

"Improving access to varenicline will be a positive step forward to help prevent the tens of thousands of deaths caused by smoking. However, a drug alone will not transform smoking rates. Services are needed to support smokers and prescribe these products."

 

"The NHS has done a good job in setting up in-hospital support to help people quit smoking, which complements the services provided in the community, said Hazel Cheeseman. "But gaps remain around the country, with services often in peril as local NHS organizations try to balance the books."

 

Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's parliament is scheduled to hold a first reading of amendments to the Tobacco Tax Act on September 24. The government plans annual tax increases from 2027 through 2030 covering cigarettes, heated tobacco, vaping liquids and other categories. It expects the reform to generate €756 million in additional revenue in 2027, rising to €3.589 billion in additional annual revenue by 2030. Ahead of the parliamentary debate, the German Association of the Tobacco Industry and Novel Products, or BVTE, launched the "Tabaksteuer mit Augenmaß" campaign backed by BAT, JTI, Philip Morris, Reemtsma and wholesale and retail groups.
Sep.23
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus distributor H&S said the zero-nicotine, zero-tar NEO vaping line will begin rolling out across FamilyMart stores in Japan from September 14, 2026, excluding some locations. The DASH line will also be sold at selected FamilyMart stores in southern Kyushu and Okinawa. Snowplus simultaneously named Japanese rock band Kishidan as a brand ambassador, combining convenience-store distribution with a broader consumer marketing push in Japan.
Sep.15
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18
China’s HTP Exports Fell 14.3% in H1 2026 as Russia and Belarus Accounted for 76% Lead
China’s HTP Exports Fell 14.3% in H1 2026 as Russia and Belarus Accounted for 76% Lead
In H1 2026, China’s HS 24041100 exports stood at $1.32 million, down 14.3% YoY, with volume falling 17.2% to 55.33 tons. Market distribution shifted drastically amid overall export drops. Exports to Russia and Belarus totaled $1 million, taking 76.0% of all shipments versus 29.5% in H1 2025. Belarus became the top destination with export value jumping 177.5%, while the Philippines, Singapore and Indonesia’s combined share slumped from 49.3% to 11.2%.Domestically, Yunnan led exporter registrations; Jiangsu and Shanghai were key suppliers, yet Anhui and Sichuan had no exports. Heavy concentration means order or declaration changes for Russia/Belarus greatly affect national aggregate data. The data shows customs entry points (not end markets), covering tobacco consumables only, excluding heating equipment and the complete HTP supply chain.
Aug.11
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives